H Tayebi-Khosroshahi, N Makhdami… - Transplantation …, 2011 - Elsevier Fifty-seven renal allograft recipients (54.8%) were males and 47 (45.2%) were females. The overall mean (± standard error) age was 40.32 ± 13.30 years. CMV IgG was positive in 95 cases (91.3%), negative in 9 (8.7%). Serologically, 76.9% patients were D + /R + 14.4% D − /R + ... Related articles - All 4 versions
G Belogi, A Rossi, A Bedeschi… - US Patent 7,935,818, 2011 - Google Patents ... path outlined in Scheme 1. Scheme 1 OH 30 wherein P1, P2 and P3 are well known protecting groups such as those used typically for the synthesis of peptides or, for instance, in the synthesis of Valacyclovir (EP 308 065), or other valine derivatives of gancyclovir (US Pat. No. ... Related articles - All 3 versions
C Costa, S Astegiano, ME Terlizzi, F Sidoti… - Transplantation …, 2011 - Elsevier ... and whole blood specimens. Each patient received a combined prolonged antiviral prophylaxis with CMV Ig for 12 months and gancyclovir or valgancyclovir for 3 weeks after postoperative day 21. Nine patients (37.5%) showed ... Related articles - All 3 versions
C Vallejo, E Riios, J de la Serna… - Expert Review of …, 2011 - ingentaconnect.com ... Treatment of CMV infection included gancyclovir or valgancyclovir in 94% of cases. ... Four patients received anti- viral prophylaxis with different combina- tions of antiviral agents and were given gancyclovir or valgancyclovir for the treatment of CMV disease. ... Related articles - All 3 versions
ML Freeman, CE Burkum, EJ Yager… - Journal of …, 2011 - Am Soc Microbiol ... sarcoma-associated herpesvirus (KSHV) (2, 16). Gancyclovir treatment of KSHV-seropositive HIV-infected 58 patients ... 59 replication in the etiology of KS since gancyclovir does not inhibit latent virus (13). Additionally, in vitro 60 ...
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
